The Centers for Medicare and Medicaid Services (CMS) announced this week that it would expand coverage for PET scans used in the diagnosis of Alzheimer's disease.
CMS has been hesitant to open reimbursements for the procedure, and the agency has long said that it would only cover one brain scan per beneficiary for a patient's...CMS Rules
Last Thursday, the Centers for Medicare and Medicaid Services (CMS) announced that it would reverse course on anti-amyloid treatments for Alzheimer's patients and cover Leqembi should it receive full approval from the U.S. Food and Drug Administration (FDA). June is Alzheimer's Awareness month.
Leqembi, produced by Biogen and Eisai,...National News
Support for Medicare coverage of the anti-Alzheimer's drug Leqembi is growing on Capitol Hill, but estimates of the drug's cost may prove to be prohibitive for the Medicare program.
Coverage of the drug through the Medicare program would raise costs for the program by $2 billion to $5 billion per year, according to a new study by...National News
As pressure mounts from stakeholders and lawmakers, Eli Lilly, producer of the experimental Alzheimer's antibody drug donanemab, is saying that it expects the Centers for Medicare and Medicaid Services (CMS) to reverse its prohibition of anti-amyloids.
A bipartisan group of nearly half of U.S. state attorneys general sent a letter to...National News
The U.S. Department of Veterans Affairs (VA) has agreed to pay for the Alzheimer's drug Leqembi, putting pressure on the Medicare program to follow suit.
Leqembi, produced by Japanese pharmaceutical manufacturer Eisai Co. in cooperation with Biogen Inc., was approved by the U.S. Food and Drug Administration (FDA) earlier this year....National News
The U.S. Food and Drug Administration (FDA) has approved the drug Leqembi (lecanemab) for the treatment of Alzheimer's disease, but patients will have a difficult time accessing the treatment due to Medicare rules and a hefty price tag.
Leqembi, developed by the Japanese pharmaceutical manufacturer Eisai and its stateside partner...
